TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be able to provide a written informed consent~* Men 18 years or older with metastatic castration-resistant prostate cancer enrolling onto the Febbo clinical trial with dasatinib therapy (must meet all inclusion criteria for dasatinib treatment study and comply with requirements of that specific clinical trial)~* Histologic confirmation of original prostate cancer diagnosis~* Presence of at least one convincing bone metastasis as defined by bone scintigraphy, computed tomography (CT) scan (magnetic resonance imaging \[MRI\] if indicated), or plain X-ray~* Must currently have castrate testosterone levels (\< 50 ng/dL) from orchiectomy or maintenance on a luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist~Exclusion Criteria:~* On the nilutamide-only arm (Arm A of the clinical therapeutic trial)~  * Note: However, if a patient crosses-over from nilutamide at the time of progression to add dasatinib therapy, he may be eligible for 18F-fluoride PET imaging protocol if he meets all inclusion criteria for this trial~* Any condition that would alter the patient's mental status, prohibiting the basic understanding and/or authorization of informed consent~* A serious underlying medical condition that would otherwise impair the patient's ability to receive treatment and imaging studies~* Expected lifespan of 12 weeks or less~* Extremely poor intravenous access, prohibiting the placement of a peripheral IV line for injection of radiotracer~* Initiation of bisphosphonate therapy less than 4 weeks from the first PET scan~* Radiation treatment to bone less than 4 weeks from first PET scan~* Radiopharmaceutical treatment to bone less than 4 weeks from first PET scan~* Treatment with granulocyte-macrophage colony stimulating factor (GM-CSF) or granulocyte CSF (G-CSF) within 4 weeks prior to first PET scan~* Inability to lie still for the imaging~* Weight \> 300 lbs. (due to equipment specifications)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 18F-Fluoride PET (Type: EXPERIMENTAL): Patients undergo fluorine F 18 sodium fluoride PET scan at baseline and then at 12 weeks after initiation of treatment with dasatinib. Dasatinib was administered under a concurrent protocol and was not considered part of the intervention on this protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metoclopramide Versus Placebo for GJ Placement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old or older~* undergoing de novo GJ placement as part of their routine clinical care~Exclusion Criteria:~* Patient pregnant~* Contraindications to metoclopramide including:~  * allergic reaction~ * pheochromocytoma~ * QTc prolongation~ * history of seizure disorder~ * extrapyramidal symptoms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metoclopramide (Type: EXPERIMENTAL): A one-time dose of promotility agent (2 mL of Metoclopramide 5 MG/ML Injectable Solution in 8 mL saline IV) will be administered at the time of GJ placement. After administration of the pro-motility drug, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
- Saline (Type: PLACEBO_COMPARATOR): A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement. After administration of the placebo, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age range 14-70 years old; ECOG performance status 0-2.~* Estimated survival time \> 6 months.~* Histological confirmed diffuse large B cell lymphoma.~* Have taken first-line chemotherapy regimen and failed.~* None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤ 1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L, serum plasminogen is normal.~* At least one measurable lesion.~* None of other serious diseases, cardiopulmonary function is normal.~* Pregnancy test of women at reproductive age must be negative.~* Patients could be followed up.~* None of other relative treatments including the traditional Chinese medicine, immunotherapy, biotherapy except anti-bone metastasis therapy and other symptomatic treatments.~* Volunteers who signed informed consent.~Exclusion Criteria:~* Disagreement on blood sample collection.~* Patients allergic of any of drug in this regimen or with metabolic disorder.~* Pregnant or lactating women.~* Serious medical illness likely to interfere with participation.~* Serious infection.~* Primitive or secondary tumors of central nervous system.~* Chemotherapy or radiotherapy contraindication.~* The evidence of CNS metastasis.~* History of peripheral nervous disorder or dysphrenia.~* Patients participating in other clinical trials.~* Patients taking other antitumor drugs.~* Patients estimated to be unsuitable by investigator.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Apatinib (Type: EXPERIMENTAL): Apatinib 500mg once daily makes an initial dose and 28 days made one treatment cycle. All patients took the drug continuously until disease progression, intolerable toxicities, and patient-requested withdrawal. Appropriate supportive care were given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18 or above~* Subjects in good general health.~* Females must have negative pregnancy test and be using adequate form of contraception~Exclusion Criteria:~* History of vaccination/infection with JE or Yellow fever or other flaviviruses~* History of residence/travel to flavivirus endemic regions~* History of anaphylaxis/serious adverse reactions~* Administration of vaccine within 30 days of study or during treatment period~* Clinically significant physical exam/medical history/lab abnormalities~* Pregnancy~* Excessive alcohol/drug abuse~* Hypersensitivity to constituents of JE-VAX®~* Blood transfusion/treatment with blood product within 6months of study and during study treatment period~* Known/suspected immunodeficiency~* Compromised blood brain barrier~* Employees of Clinical Research Organization (CRO)/study site staff~* Any other condition which would exclude subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ChimeriVax™-JE (Type: EXPERIMENTAL): Participants received dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine and saline placebo into different arms.
- JE-VAX® (Type: ACTIVE_COMPARATOR): Participants received 1 dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a dose of saline placebo into a different arm on Day 30.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy pediatric subjects 6 months to 17 years of age,~2. Individuals' parent(s) or legal guardian(s) willing to provide written informed consent,~3. Individuals in good health,~4. Individuals/Individuals' parent(s)/legal guardian(s) willing to allow for serum samples to be stored beyond the study period,~5. Individuals willing to provide informed assent (where applicable).~Exclusion Criteria:~1. Individuals' parent(s)/legal guardian(s) not able to understand and follow study procedures,~2. History of any significant illness,~3. History of any chronic medical condition or progressive disease,~4. Presence of medically significant cancer,~5. Known or suspected impairment/alteration of immune function,~6. Presence of any progressive or severe neurologic disorder,~7. Presence of any bleeding disorders or conditions that prolongs bleeding time,~8. History of allergy to vaccine components,~9. Receipt of any other investigational product within 30 days prior to entry into the study,~10. History of previous H5N1 vaccination,~11. Receipt of any other type of seasonal vaccination within 2 months prior to entry into the study,~12. Receipt of any other vaccine within 2 weeks prior to entry into the study,~13. Body temperature ≥38°C (≥100.4° F) and/or acute illness within 3 days of intended study vaccination,~14. Pregnant or breast feeding,~15. Females of childbearing potential refusing to use acceptable method of birth control,~16. Body mass index (BMI) ≥ 35 kg/m2,~17. History of drug or alcohol abuse,~18. Any planned surgery during study period,~19. Individuals conducting the study and their immediate family members,~20. Individuals with behavioral or cognitive impairment or psychiatric diseases,~21. Individuals diagnosed with any growth disorders.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- aH5N1c-High dose (Type: EXPERIMENTAL): None
- aH5N1c-Low dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type 1 or 2 diabetes mellitus must have a documented clinical diagnosis of painful diabetic peripheral neuropathy with symptoms and signs for at least 6 months, and pain present at the time of screening~* Diagnosis must include pain plus reduction or absence of pin sensibility and/or vibration sensibility on Total Neuropathy Score - Nurse (TNSn) examination in lower and/or upper extremities at screening~* The investigator considers the patient's blood glucose to be controlled by diet, or hypoglycemics, or insulin for at least 3 months prior to enrolling in the study~* Patients have been taking analgesic medications for the condition for at least 3 months prior to screening (patients taking opioid analgesics must be dissatisfied with current treatment, and patients taking non-opioid analgesics must be dissatisfied with current analgesia)~* Patients currently requiring opioid treatment must be taking daily doses of an opioid-based analgesic equivalent to \<=160mg of oral morphine~Exclusion Criteria:~* Significant history of pulmonary, gastrointestinal, endocrine, metabolic (except diabetes mellitus), neurological, psychiatric disorders (resulting in disorientation, memory impairment or inability to report accurately as in schizophrenia)~* History of moderate to severe hepatic impairment~* Severely impaired renal function~* Clinically significant laboratory abnormalities~* Clinically significant cardiac disease~* History of seizure disorder or epilepsy~* History of any other clinically significant disease that in the investigator's opinion may affect efficacy or safety assessments or may compromise patient safety during study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tapentadol Extended Release (ER) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Subjects diagnosed with non-valvular atrial fibrillation with an indication for the anticoagulation therapy,~* Subjects with severe renal function impairment defined as creatinine clearance between 15 and 30 mL/min by Cockcroft-Gault formula,~* Male and female patients, age =18 years at entry~Exclusion criteria:~* Contraindications to Pradaxa (history of a serious hypersensitivity reaction to Pradaxa, active pathological bleeding, patients with mechanical prosthetic heart valve),~* Creatinine clearance \<15ml/min or patients with End Stage Renal Disease on dialysis,~* Creatinine clearance \>30 ml/min,~* Pre-menopausal women (last menstruation less than one year prior to informed consent) who are nursing or pregnant, or are of child bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study. Acceptable methods of birth control include abstinence, tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, double barrier method and vasectomised partner,~* Patients who are participating in another drug study,~* Patients who have participated in another drug study within 6 weeks,~* Patients considered unreliable by the investigator concerning the requirements for participating in the study, including a follow-up interview,~* Any condition the investigator believes would not allow safe participation in the study,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dabigatran etexilate (Type: OTHER): 75mg BID by oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Glucose Sensor Profiles in Non-Diabetic Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \> 8 years~* Body mass index (BMI) between the 10th to 90th percentile for age and sex (based on CDC, 2000 nomogram) and \< 28 kg body weight/meter in adult subjects~* No significant chronic illness or taking any acute or chronic medications that might affect glucose metabolism.~Exclusion Criteria:~* History of diabetes or positive islet cell antibody testing

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to randomisation (Visit 2)~* Current treatment: metformin monotherapy or metformin in any combination with 1 or 2 other OADs including an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV) inhibitors, alpha-glucosidase inhibitors, thiazolidinediones (TZDs) all with unchanged dosing for at least 12 weeks prior to randomisation (Visit 2)-metformin: alone or in combination (including fixed combination) must be at least 1000 mg daily~* HbA1c 7.0-10.0% (both inclusive) by central laboratory analysis~* BMI (Body Mass Index) no higher than 45.0 kg/m\^2~Exclusion Criteria:~* Treatment with glucagon-like peptide 1 (GLP-1) receptor agonist within the last 12 weeks prior to Visit 2~* Suffer from a life threatening disease (e.g. cancer)~* Females of childbearing potential who are pregnant (as determined by central laboratory beta-human chorionic gonadotropin (beta-hCG), breast feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive methods as required by law or practise \[for Germany, adequate contraceptive methods are: implants, injectables, combined oral contraceptives, hormonal IUD, sexual abstinence or vasectomised partner\])

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg Simple (Type: EXPERIMENTAL): None
- IDeg Step wise (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Magnesium Sulphate on the Time Course of Rocuronium Induced Neuromuscular Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anaesthesiology (ASA) status I or II~* Adults, aged 18 years to 60 years~* Scheduled for elective surgery lasting longer than 120 min without need for continuous curarisation~Exclusion Criteria:~* A history of allergy or hypersensitivity to rocuronium~* Neuromuscular disease~* Preoperative medications known to influence neuromuscular function (for instance, certain antibiotics and anticonvulsants)~* Electrolyte abnormalities~* Hepatic or renal insufficiency~* Patients with a body mass index \<19 or \>28 kg m2~* Pregnant or breastfeeding women~* Expected difficult intubation or mask ventilation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Physiologic saline (Type: PLACEBO_COMPARATOR): None
- Magnesium sulphate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Ages 18-75 years~* Men and women~* At least one cardiovascular risk factor (i.e hypertension, dyslipidemia, smoking/formerly smoker, premature familial coronary artery disease \[CAD\], microalbuminuria)~* Written informed consent given~Exclusion Criteria:~* Unwillingness~* Age \< 18 or \> 75 years~* Unstable cardiovascular condition~* Unstable medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Structured multi intervention (Type: OTHER): Structured multi intervention to reach predefined glycemic and blood pressure goals as well as activity and weight goal
- Standard of care (Type: OTHER): Standard care with or without structured care according to national guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete